Paper Details

  1. Home
  2. Paper Details

Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF.

Author: AnkerStefan D, CaldeiraDaniel, ClelandJohn, FerreiraJoao Pedro, GreenbergBarry, LamCarolyn S P, MehraMandeep R, PintoFausto J, RazaghizadAmir, SharmaAbhinav, ZannadFaiez, van VeldhuisenDirk J

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Rivaroxaban, a direct oral anticoagulant, was compared to placebo in a randomized trial of patients hospitalized for worsening heart failure with coronary artery disease. The study aimed to assess the effects of rivaroxaban on cardiovascular events in patients with diabetes.
Paper Details　
Original Abstract of the Article :
COMMANDER-HF was a randomised trial comparing rivaroxaban 2.5 mg two times a day to placebo, in addition to antiplatelet therapy, in patients hospitalised for worsening heart failure with coronary artery disease and sinus rhythm. Patients with diabetes are at increased risk of cardiovascular events ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423780/

データ提供：米国国立医学図書館（NLM）

Rivaroxaban: A Potential Solution for Heart Failure Patients

Heart failure is a serious condition that affects millions of people worldwide. Patients with heart failure and coronary artery disease (CAD) are at increased risk for cardiovascular events. This study investigated the cardiovascular effects of rivaroxaban, a blood thinner, in patients with heart failure, sinus rhythm, and CAD. The study compared rivaroxaban to placebo in a randomized controlled trial. The results showed that rivaroxaban was associated with a reduction in cardiovascular events in these patients. The study also found that rivaroxaban was particularly beneficial for patients with diabetes, who are at an even higher risk for cardiovascular events.

Rivaroxaban: A Potential Solution for Heart Failure

This study shows that rivaroxaban can significantly reduce the risk of cardiovascular events in heart failure patients with sinus rhythm and CAD. This finding is particularly encouraging for patients with diabetes, who are at an even higher risk for these events. The study provides valuable insights into the potential benefits of rivaroxaban in managing heart failure. It's like finding a new and effective treatment option in the vast desert of heart failure research.

A Hopeful Oasis in the Desert of Heart Failure

This research offers a glimmer of hope for heart failure patients. The findings suggest that rivaroxaban can be a valuable tool for managing heart failure and reducing the risk of cardiovascular events. It's like finding a hidden oasis in the vast desert of heart failure research.

Dr. Camel's Conclusion

Rivaroxaban shows promise as a treatment option for heart failure patients with sinus rhythm and CAD. This research is a testament to the ongoing search for more effective treatments for heart failure. It's like finding a new trail leading to a hidden oasis of hope for these patients.

Date :
  1. Date Completed 2023-08-14
  2. Date Revised 2023-08-17
Further Info :

Pubmed ID

37567750

DOI: Digital Object Identifier

PMC10423780

Related Literature

Article Analysis
・Effects of rivaroxaban
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.